Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 1

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
433,848 

See accompanying notes to the condensed consolidated financial statements.

 4Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 

(Currency expressed in United States Dollars (“US$”))

    As of   Note  June 30,  December 31,     2025  2024     (Unaudited)  (Audited) LIABILITIES AND STOCKHOLDERS’ EQUITY         CURRENT LIABILITIES         Trade payables (including $2,398 and $nil of trade payables from related parties as of June 30, 2025 and December 31, 2024 respectively)  8   1,367,535   1,503,326 Other payables and accrued liabilities      307,340   284,108 Current portion of operating lease liabilities  5   55,809   50,816 Advance payment from customer      11,348   95,879 Amount owing to directors      15,789   17,174 Total current liabilities      1,757,821   1,951,303              NON-CURRENT LIABILITIES            Non-current portion of operating lease liabilities  5   141,347   159,741 Deferred tax liabilities  4   -   - Total non-current liabilities      141,347   159,741 TOTAL LIABILITIES     $1,899,168  $2,111,044              STOCKHOLDERS’ EQUITY            As at June 30, 2025, common stock, no par value; 300,000,000 shares authorized and 1,796,597 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and